Cancer immunotherapy, with immune checkpoint blockade, has provided profound benefit for patients with late-stage cancers. These advances provide proof of concept that our immune systems can eliminate cancer, but the successes to date only occur in a small proportion of cancer patients. Broadening responses to a majority of patients is still just beyond reach with traditional therapeutic combinations.
Shattuck was founded to solve the challenge of consolidating checkpoint blockade and TNF receptor agonists into single therapeutics.
The Agonist Redirected Checkpoint (ARC) platform emerged as the first therapeutic modality to achieve this goal, and Shattuck has developed an ARC product development engine that has yielded over 200 ARC drug candidates to date. Across the product pipeline, ARC therapeutics provide superior potency to antibody-based therapeutics targeting the same pathways.